GUILFORD, Conn.–(BUSINESS WIRE)–BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that, in light of the significant demands placed on her time by a number of other business commitments, Dr. Nancy Stagliano has resigned as a director of the company.
“Nancy has played a key role in providing oversight and guidance to Bioasis over the past two years,” said Dr. Deborah Rathjen, Executive Chair and Chief Executive Officer of Bioasis. “We are grateful for her contributions and wish her well in her other endeavours.”
Given Dr. Stagliano’s resignation, she will no longer be standing for re-election at the Company’s annual meeting of shareholders to be held on December 5, 2019. As a result, only the four remaining members of Bioasis’ board of directors (being Dr. Deborah Rathjen, John Curran, David Wurzer and Dr. Mario Saltarelli) will be nominated for election at the meeting.
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3 ™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. The Company maintains headquarters in Guilford, Conn., United States. Bioasis trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more information about the company, please visit www.bioasis.us.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.